Writer and featured expert
Jessica and her views on science, global health, and careers have been featured through a number of outlets, including the American Society of Tropical Medicine and Hygiene, Global Network for Neglected Tropical Diseases, PLoS Blogs, and Global Health Now. She was also featured among the 100 Women Leaders in Global Health by Graduate Institute Geneva.
- Gaining insights across development silos, DevPolicy Blog, 2016
- What it will take to mobilize a global fight against viral hepatitis, Global Health Now, 2016
- It’s time we get realistic about addressing HIV, PLoS Blogs, 2016
- Why I love the International AIDS Conference, Global Health Now, 2016
- The Top 3 Opportunities for mHealth, a $42.12 Billion Industry by 2020, TechChange, 2015
- Dengue: Why You Need to Know About It, PLoS Blogs, 2014
- World Malaria Day Perspectives: Jessica Taaffe, Global Health and Science Consultant, American Society of Tropical Medicine and Hygiene, 2014
- The World Bank, Opportunities for Young and Motivated Individuals, NIH Visiting Fellows Committee Newsletter, 2014
- American Society of Tropical Medicine and Hygiene Member Spotlight, 2012
- Worm tales: One scientist’s inspiration to turn tropical diseases into ‘stories told by a past generation’, Global Network for Neglected Tropical Diseases, 2012
Academic Publications/Technical Reports
Bali, S., and Taaffe, J. (2017) Exploring the synergies between the SDGs and Global Health Security Agenda for a sustainable and resilient world. J of Public Health Policy
Taaffe, J., and Wilson, D. (2016) Mobilizing a Global Movement for Hepatitis: Lessons Learned from the HIV Response. Global Public Health, 1-16.
Taaffe J, Cheikh N, Wilson D. (2016) The use of cash transfers for HIV prevention - are we there yet? Afr J AIDS Res 15(1):17-25.
Bassett IV, Wilson D, Taaffe J, et al. (2015) Financial incentives to improve progression through the HIV treatment cascade. Curr Opin HIV AIDS 10(6):451-63
Taaffe, J, Fraser-Hurt, N, Gorgens, M, Harimurti, P. (2014) A Comprehensive Review of Empirical and Modeled HIV Incidence Trends (1990-2012) World Bank Policy Research Working Paper No. 7042
Wilson D, Taaffe J, Fraser-Hurt N, et al. (2014) The economics, financing and implementation of HIV treatment as prevention: what will it take to get there? Afr J AIDS Res 13(2):109-19.
McGary, CS, Cervasi, B, Chahroudi, A, Micci, L, Taaffe, J, et al. (2014) Increased stability and limited proliferation of CD4+ central memory T cells differentiate nonprogressive simian immunodeficiency virus (SIV) infection of sooty mangabeys from progressive SIV infection of rhesus macaques. J Virol 88(8):4533-42.
Klatt, N., Bosinger, S., Specht, A., Taaffe, J, et al. (2014) Limited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals. PLoS Pathog 10(8):e1004345.
Taaffe JE, Bosinger SE, Del Prete GQ, et al. (2012) CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques. J Med Primatol (1):24-42.
Taaffe J, Chahroudi A, Engram J, et al. (2010) A five-year longitudinal analysis of sooty mangabeys naturally infected with simian immunodeficiency virus reveals a slow but progressive decline in CD4+ T-cell count whose magnitude is not predicted by viral load or immune activation. J Virol 84(11):5476-84.
Riddick, NE., Hermann, EA, Loftin, LM, Elliott, ST, Wey, WC, Cervasi, B, Taaffe, J, et al. (2010) A novel CCR5 mutation common in sooty mangabeys reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in vivo. PLoS Pathog 6(8):e1001064.
Wang S, Parker C, Taaffe J, et al. (2008) Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 26(29-30):3626-33.
Wang S, Taaffe J, Parker C, et al. (2006) Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol 80(23):11628-37.